Biodexa pharmaceuticals plc (“biodexa” or the “company”) regains compliance for continued listing on nasdaq

November 12, 2024 biodexa pharmaceuticals plc (“biodexa” or the “company”) regains compliance for continued listing on nasdaq biodexa pharmaceuticals plc, (nasdaq: bdrx), a clinical stage biopharmaceutical company developing a pipeline of innovative products for the treatment of diseases with unmet medical needs announces that the company has been formally notified that the nasdaq hearings panel (the “panel”) of the nasdaq stock market llc (“nasdaq”) determined that the company has regained compliance with the $1.00 minimum bid price requirement for continued listing on nasdaq as set forth in nasdaq listing rule 5550(a)(2) (the “minimum bid price requirement”). as previously disclosed, the company received notice from nasdaq on august 27, 2024, informing the company that it was not in compliance with the minimum bid price requirement.
BDRX Ratings Summary
BDRX Quant Ranking